N4P

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that further to the Company's announcement dated 11 February...

N4 Pharma’s Nigel Theobald discusses highlights from their interim results, key findings in the optimisation work, progress of the two MTA’s, patents and what investors can expect in the next...

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss interim results for the six months ended 30 June 2021. Nigel talks us through the highlights, talks about...

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30...

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its current in vivo work streams due...

N4 Pharma plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its current work streams. Collaborations As...

SP Angel’s Vadim Alexandre discusses N4 Pharma plc in this exclusive interview with DirectorsTalk.

N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst Vadim Alexandre joins DirectorsTalk. Vadim talks us through the main points of their latest research note, explains...

N4 Pharma’s Nigel Theobald discusses the Material Transfer Agreements, collaborating with more partners, the in vivo studies, how the work done under the MTA may negate the need for the...

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its operations update. Nigel explains what is involved in the Material Transfer Agreements that have been announced, whether these...